Nicolaus Radford, who founded Nauticus Robotics and took it all the way to IPO, shares details of his new company, PersonaAI. Image via LinkedIn

For his next act, Houston entrepreneur Nicolaus Radford has started — in what he describes as an "anti-stealth" capacity — a new company that hopes to bring humanoid robotics out of science fiction novels and into manufacturing floors.

Radford, who saw his last company, Nauticus Robotics, from founding to IPO, left the company in January. He tells InnovationMap that he started receiving some compelling offers at other robotics companies, but none of them felt like a fit. However, he just couldn't get the idea of advancing humanoid robotics out of his head.

"Humanoids are the holy grail of all of robotics," Radford says. "It's what every science fiction writer's always dreamed about.

"It is the future," he continues. "And now with this generative AI moment of 2022 where these machines look a lot more capable, flexible, reprogrammable — they can reason in real time. That's a huge deal."

Radford says he got a call from his friend, Jerry Pratt, who was the CTO at humanoid robotics company Figure AI. Pratt and Radford both worked in robotics at NASA and each have decades of experience in the tech world. The conversation really sealed the deal for Radford, and the two officially launched Persona AI in a LinkedIn post that Radford says shocked him with how much interest the community had.

Radford says that with all this interest, he wants to open up the company to more co-founders than just himself and Pratt, who's based in Florida.

"We're going to give a significant amount of the company out to the early joiners, more so than is probably typical," Radford says. "And it's because we know it takes a village, and we want to highlight that to everybody."

"We're trying to crowdsource the company," he continues. "We've coined that we're anti stealth."

Specifically, Radford says he's looking at growing the team to about 25 people in the next year, alongside raising early funding. He's looking for people with a diverse tech background with well-rounded experience.

"Robotics and humanoids in particular are just so multidisciplinary," Radford says. "Humanoids are a hundred-thousand-piece puzzle, and you're trying to put this puzzle together."

And for Radford, assembling that puzzle in Houston is of utmost importance. The company is headquartered here, and Radford is currently working with The Ion to set up an office there.

"We're exceptionally excited to put (the company) in Houston," he says. "It would be incredible for the city — there's a lot of industrial manufacturing here and a lot of warehousing. ... I still have this desire to shine a light on Houston's tech scene because I believe it is unsung, underappreciated, and quite capable."

The potential for this technology is huge — Radford estimates it as a $3 trillion market — but the first industry he plans on tackling is automotive, but he also sees promise in the medical, energy, and home industries.

"We think automotive is going to be a first-mover market. There's a lot of publicly announced partnerships between advanced robotics companies and humanoid companies and automotive," he says. "These folks are showing a willingness to put something out in the press that says they're developing a humanoid or piloting a humanoid. That's huge.

With this expressed interest, technology advancement, and large labor shortage, Radford is convinced now is the time for humanoid robotics — and for Persona AI.

"We're at a technology tipping point where it makes sense that these machines can do this, and there's an investment community willing to finance it," Radford says. "I think the first time in all of robotic history we're closer than we've ever been to making this a reality."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”